米拉德美坦(MDM2抑制剂)在晚期脂肪肉瘤、实体瘤或淋巴瘤患者中的首次人体I期研究
这项首次人体I期研究评估了MDM2抑制剂米拉德美坦在晚期实体瘤或淋巴瘤患者中的安全性、药代动力学、药效动力学和初步疗效,采用每日口服的延长/连续或间歇给药方案,主要目标是确定推荐II期剂量和方案。2013年7月至2018年8月共入组107例患者,最常见3/4级药物相关不良事件为血小板减少症(29.0%)、中性粒细胞减少症(15.0%)和贫血(13.1%)。推荐剂量方案为260 mg每日一次,每28天周期的第1-3天和第15-17天给药(即3/14天),该方案下上述事件发生率分别为15.0%、5.0%和0%。
要点
- 推荐II期剂量方案为米拉德美坦260 mg每日一次,每28天周期第1-3天和第15-17天给药(3/14天间歇方案)。
- 全队列(N=107)疾病控制率为45.8%(95% CI 36.1-55.7),中位无进展生存期为4.0个月(95% CI 3.4-5.7)。
- 去分化脂肪肉瘤亚组(n=53)疾病控制率为58.5%(95% CI 44.1-71.9),中位无进展生存期为7.2个月。
核心结论
- 米拉德美坦3/14天间歇给药方案可减轻剂量限制性血液学异常,同时维持疗效。
- 米拉德美坦在去分化脂肪肉瘤中显示出显著的单药活性,已促成一项随机III期试验(MANTRA)。
研究设计与样本
- 首次人体I期研究,评估米拉德美坦在晚期实体瘤或淋巴瘤患者中的安全性、药代动力学、药效动力学和初步疗效。
- 患者每日口服米拉德美坦,采用延长/连续方案(每28天周期的第1-21天或第1-28天)或间歇方案(每28天周期的第1-7天,或第1-3天和第15-17天)。
- 主要目标为确定推荐II期剂量和方案;次要目标包括根据标准评估标准评价肿瘤缓解;预设按肿瘤类型进行分析。
- 安全性和疗效分析纳入所有接受米拉德美坦的患者。
主要发现
- 2013年7月至2018年8月共入组107例患者并接受米拉德美坦治疗。
- 最常见的3/4级药物相关不良事件为血小板减少症(29.0%)、中性粒细胞减少症(15.0%)和贫血(13.1%)。
- 在推荐剂量方案(260 mg每日一次,每28天周期的第1-3天和第15-17天,即3/14天)下,血小板减少症、中性粒细胞减少症和贫血发生率分别为15.0%、5.0%和0%。
- 全队列(N=107)疾病控制率为45.8%(95% CI 36.1-55.7),中位无进展生存期为4.0个月(95% CI 3.4-5.7)。
- 去分化脂肪肉瘤亚组(n=53)疾病控制率为58.5%(95% CI 44.1-71.9),中位无进展生存期为7.2个月;采用推荐间歇方案(n=16)时分别为62.0%(95% CI 35.4-84.8)和7.4个月。
关键数值与推荐
- 推荐II期剂量和方案:米拉德美坦260 mg每日一次,每28天周期的第1-3天和第15-17天给药(即3/14天)。
- 全队列(N=107)疾病控制率45.8%(95% CI 36.1-55.7),中位无进展生存期4.0个月(95% CI 3.4-5.7)。
- 去分化脂肪肉瘤亚组(n=53)疾病控制率58.5%(95% CI 44.1-71.9),中位无进展生存期7.2个月;推荐间歇方案(n=16)下疾病控制率62.0%(95% CI 35.4-84.8),中位无进展生存期7.4个月。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. PATIENTS AND METHODS: In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended/continuous (days 1-21 or 1-28 every 28 days) or intermittent (days 1-7, or days 1-3 and 15-17 every 28 days) schedules. The primary objective was to determine the recommended phase II dose and schedule. Secondary objectives included tumor response according to standard evaluation criteria. Predefined analyses by tumor type were performed. Safety and efficacy analyses included all patients who received milademetan. RESULTS: Between July 2013 and August 2018, 107 patients were enrolled and received milademetan. The most common grade 3/4 drug-related adverse events were thrombocytopenia (29.0%), neutropenia (15.0%), and anemia (13.1%). Respective rates at the recommended dose and schedule (260 mg once daily on days 1-3 and 15-17 every 28 days, ie, 3/14 days) were 15.0%, 5.0%, and 0%. Across all cohorts (N = 107), the disease control rate was 45.8% (95% CI, 36.1 to 55.7) and median progression-free survival was 4.0 months (95% CI, 3.4 to 5.7). In the subgroup with dedifferentiated liposarcomas, the disease control rate and median progression-free survival were 58.5% (95% CI, 44.1 to 71.9) and 7.2 months overall (n = 53), and 62.0% (95% CI, 35.4 to 84.8) and 7.4 months with the recommended intermittent schedule (n = 16), respectively. CONCLUSION: An intermittent dosing schedule of 3/14 days of milademetan mitigates dose-limiting hematologic abnormalities while maintaining efficacy. Notable single-agent activity with milademetan in dedifferentiated liposarcomas has prompted a randomized phase III trial (MANTRA).
引用
- Gounder MM, Bauer TM, Schwartz GK, et al. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol. 2023. PMID: 36669146. doi:10.1200/JCO.22.01285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。